We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-12.45%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$572M
AUM Growth
-$77.3M
Cap. Flow
+$9M
Cap. Flow %
1.57%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$23.2M
2
GILD icon
Gilead Sciences
GILD
+$2.14M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$530K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$696M
$143M 24.97%
16,390,000
– –
BIIB icon
2
Biogen
BIIB
$30B
$139M 24.26%
643,000
– –
INVA icon
3
Innoviva
INVA
$1.55B
$111M 19.4%
7,277,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$80.8M 14.14%
1,103,282
+27,882
+3% +$2.14M
NBIX icon
5
Neurocrine Biosciences
NBIX
$16.8B
$47.8M 8.36%
346,426
-123,574
-26% -$16.9M
AMRN
6
Amarin Corp
AMRN
$299M
$22.1M 3.87%
1,242,531
– –
CYTK icon
7
Cytokinetics
CYTK
$10.5B
$21M 3.68%
+300,000
New +$23.2M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$5.56M 0.97%
1,094,168
+94,168
+9% +$530K
VOR icon
9
Vor Biopharma
VOR
$1.15B
$1.46M 0.26%
30,900
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$533K 0.09%
185,183
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sarissa Capital Management held 10 positions worth $572M, down 12% from $649M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q1 2024 filing shows 1 new, 2 increased and 1 reduced positions. Its largest new stake was Cytokinetics: 300,000 shares worth $21M. The largest sale was Neurocrine Biosciences, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's largest Q1 2024 buy was Cytokinetics: 300,000 shares worth $21M.
  • Sarissa Capital Management added most to Gilead Sciences in Q1 2024, an estimated $2.14M increase.
  • Sarissa Capital Management's biggest Q1 2024 reduction was Neurocrine Biosciences, cutting an estimated $16.9M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $572M portfolio in Q1 2024.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q1 2024.
  • Sarissa Capital Management's portfolio value fell 12% quarter-over-quarter to $572M.

Based on Sarissa Capital Management's 13F filing for Q1 2024, filed 15 May 2024.